Nomos Corp. v. BrainLAB, Inc.

195 F. Supp. 2d 606, 2002 U.S. Dist. LEXIS 6454, 2002 WL 531470
CourtDistrict Court, D. Delaware
DecidedMarch 28, 2002
DocketCIV.A.98-788-JJF
StatusPublished
Cited by1 cases

This text of 195 F. Supp. 2d 606 (Nomos Corp. v. BrainLAB, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Nomos Corp. v. BrainLAB, Inc., 195 F. Supp. 2d 606, 2002 U.S. Dist. LEXIS 6454, 2002 WL 531470 (D. Del. 2002).

Opinion

MEMORANDUM OPINION

FARNAN, District Judge.

This action was brought by Plaintiff, NOMOS Corporation (“NOMOS”) against Defendants BrainLAB, Inc. and Brain-LAB USA, Inc. (collectively “BrainLAB”) alleging infringement of United States Patent No. 5,411,026 (the “’026 Patent”). The parties briefed their respective positions on claim construction, and the Court conducted a Markman hearing on the disputed terms in the ’026 Patent. This Memorandum Opinion presents the Court’s construction of the disputed terms in the ’026 Patent.

BACKGROUND

I. Introduction to the Technology Generally

The ’026 Patent describes a method and apparatus for verifying the position of a *609 cancerous lesion on a patient’s body which is to be treated by a radiation therapy device operating in accordance with a radiation therapy plan. (’026 Patent, col. 1, 1. 7-10). A frequent problem in treating patients with these lesions is identifying where the lesion is located at the time the radiation therapy treatment is occurring. Conventionally, the location of the lesion is determined with a CT scan of the patient. From this CT scan, the surgeon develops a radiation treatment plan to highlight the areas he or she wants treated with radiation. As a result of the positioning of the patient on the treatment table and the lapse of time between the CT scan and the radiation therapy treatment, the location of the lesion may change. In the past, radiation therapy plans targeted a larger area of the patient than was necessary to account for the possible change in location of the lesion. By targeting a larger area than the lesion actually occupied, however, a patient’s healthy tissue and organs could be exposed to damaging radiation. To avoid this problem, physicians would often decrease the dose of radiation administered to the patient. However, the decreased dose of radiation was often insufficient to properly treat the target area. The technology of the ’026 Patent is meant to avoid these problems with conventional radiation therapy treatment, and provide a means by which the location of the lesion to be treated by the radiation therapy device can be verified within the body of the patient for use in a radiation treatment plan for the patient.

II. The’026 Patent

The ’026 Patent discloses a method and apparatus for verifying the position of a lesion in a patient’s body by comparing the location of the lesion as depicted in a CT scan with the position of the lesion as depicted in an ultrasound images. (’026 Patent, Abstract). The invention includes the steps of (1) disposing the patient on a treatment table of a radiation therapy device, (2) disposing on the treatment table a means for generating an ultrasound image, (3) generating at least one two-dimensional ultrasound image of the lesion in the patient’s body, (4) outlining the outer surface of the lesion in the ultrasound image and (5) comparing the outlines of the lesion in the ultrasound image to the outline of the lesion generated by one of the diagnostic images. (’026 Patent, col. 2, 1. 45-62).

The specification of the ’026 Patent discloses a system used with a radiation therapy device such as a linear accelerator that delivers precise amounts of radiation to the lesion. According to the specification the claimed invention uses an ultrasound probe mounted to the treatment table so that it is maintained perpendicular to the treatment table. (’026 Patent, col. 1, 11. 17-22). The ultrasound probe is also located above the lesion to be treated, and is moved downward to contact the patient. (’026 Patent, col. 1, 11. 17-22 & Fig. 5).

The ultrasound probe then may be rotated or moved along the long axis of the treatment table to generate a series of ultrasound images of the lesion. (’026 Patent, col. 7, 11. 27-31). These ultrasound images need to be compared with the diagnostic images taken by the CT scan in order-to determine the precise location of the lesion. To effectuate this comparison, the position of the ultrasound probe must be determined for each ultrasound image generated. The specification of the ’026 Patent describes the use of a position sensing system consisting of light emitting diodes (LEDs) or ultrasonic emitters mounted to the ultrasound probe and a sensor to identify the location of the ultrasound probe with respect to the linear accelerator so that the images generated by the ultrasound probe can be accurately compared .to the original images generated by the CT scan of the patient and a more *610 precise treatment area can be determined. (’026 Patent, col. 8,11.1-38).

DISCUSSION

I. The Legal Principles of Claim Construction

Claim construction is a question of law. Markman v. Westview Instruments, Inc., 52 F.3d 967, 977-78 (Fed.Cir.1995), aff 'd, 517 U.S. 370, 388-90, 116 S.Ct. 1384, 134 L.Ed.2d 577 (1996). When construing the claims of a patent, a court considers the literal language of the claim, the patent specification and the prosecution history. Markman, 52 F.3d at 979. A court may consider extrinsic evidence, including expert and inventor testimony, dictionaries, and learned treatises, in order to assist it in construing the true meaning of the language used in the patent. Id. at 979-80 (citations omitted). A court should interpret the language in a claim by applying the ordinary and accustomed meaning of the words in the claim. Envirotech Corp. v. Al George, Inc., 730 F.2d 753, 759 (Fed.Cir.1984). However, if the patent inventor clearly supplies a different meaning, the claim should be interpreted accordingly. Markman, 52 F.3d at 980 (noting that patentee is free to be his own lexicographer, but emphasizing that any special definitions given to words must be clearly set forth in patent). If possible, claims should be construed to uphold validity. In re Yamamoto, 740 F.2d 1569, 1571 & n.* (Fed.Cir.1984) (citations omitted).

II. The Meaning Of The Disputed Terms of the ’026 Patent

NOMOS asserts that BrainLAB’s Ex-acTrac device infringes Claims 1, 5, 6, 7, 8, 14 and 15 of the ’026 Patent. Claim 5 of the ’026 Patent is dependant on Claim 1 of the ’026 Patent. Claims 7, 8, 14 and 15 of the ’026 Patent are dependent on Claim 6 of the ’026 Patent. The parties have focused their arguments on Claims 1 and 6 of the ’026 Patent, and therefore, the Court will likewise focus its discussion on Claims 1 and 6 of the ’026 Patent. 1

A. The Disputed Terms In Claim 1 Of The ’026 Patent

In full, Claim 1 of the ’026 Patent provides:

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
195 F. Supp. 2d 606, 2002 U.S. Dist. LEXIS 6454, 2002 WL 531470, Counsel Stack Legal Research, https://law.counselstack.com/opinion/nomos-corp-v-brainlab-inc-ded-2002.